5/10/2022

speaker
Nadia
Operator

Thank you for your patience everyone as Invercare first quarter 2022 conference call and webcast will begin in one minute's time. If you would like to ask a question at the end of the presentation please press star followed by the number one on your telephone keypad. Thank you. Thank you. Good morning, ladies and gentlemen, and thanks for standing by. Welcome to the Invercare First Quarter 2022 conference call and webcast. After the management overview, we will open the call to questions. Investors and analysts interested in asking questions will need to dial in as questions cannot be submitted via the webcast. For the first part of the call, all phone lines have been placed on mute. This conference is being recorded Tuesday, May 10th, 2022. I will now turn the call over to Lois Lee, Invocare's Director of Treasury, Investor Relations, and Corporate Communications.

speaker
Lois Lee
Director of Treasury, Investor Relations, and Corporate Communications

Thank you, Nadia. Joining me on today's call from Invocare are Matt Monahan, Chairman, President, and Chief Executive Officer, and Kathy Lenahan, Senior Vice President and Chief Financial Officer. Today, we will be reviewing our first quarter 2022 finance results and providing investors with an update on our full year outlook. To help investors follow along, we have created slides to accompany this webcast. For those dialing in, you can find a link to our webcast slide presentation at global.invacare.com slash investor dash relations. Further information can be found in our SEC filings. Before math begins, I'd like to note that during today's call, we may make forward-looking statements about the company that, by their nature, address matters that are uncertain. Actual future results may differ materially from those expressed in our statement today due to various uncertainties, and I'm referring to the cautionary statement included on the second page of our webcast slides and on our first quarter earnings release. For an explanation of the items discussed in today's call that are considered to be non-GAAP financial information, such as constant currency net sales, constant currency SG&A, free cash flow, and adjusted EBITDA, please see the notes in the appendix of our webcast slides and in the related reconciliations in the slides and the earnings release posted on our website. I will now turn the call over to Matt Monahan.

speaker
Matt Monahan
Chairman, President, and Chief Executive Officer

Thank you, Lois, and good morning. Beginning on slide three, we started 2022 with strong revenue growth led by sales of mobility and seating as new high-value products gained traction with customers and as pandemic-related healthcare access continue to improve. We're encouraged by strong demand across all our product lines and regions and continued elevated backlog, reflecting the strength of our portfolio. Our innovation engine, which didn't stop during COVID, has continued to produce new, compelling products that drive strong demand. At the same time, and as noted in our fourth quarter 21 release, we anticipated temporary challenges would negatively impact gross margin in the first quarter, To address this, we've emphasized our more clinically valuable products and discontinued parts of our product ranges we can't support in the current environment. We've instituted price increases to offset higher costs, and we've taken steps to optimize value to our customers, like aggregating orders and moving shipping locations. In addition, we expect to take further actions this year that will improve operating results. We anticipate the benefit of mixed shifts and pricing actions to be increasingly impactful in the sequential quarters. Overall, first quarter results were in line with our expectations, reflecting the seasonality of our business and the time lag of mitigating actions. During the slide four, after a deep strategic review of our current projects and processes and with the assistance of third-party experts, we've identified opportunities to improve our business to better serve our customers and to yield better results. These can be broadly classified in two core areas. First, As we announced last week, we've taken actions to streamline our operations and lower costs by simplifying the organization, especially leveraging technology to eliminate non-core administrative processes. Actions taken year-to-date through early May are expected to provide a benefit of approximately $6 million in 2022 and approximately $9 million on an annual run rate basis. Overall, once restructuring actions are completed, we anticipate a benefit of approximately $11 million in 2022 and at least $20 million of an annual run rate-based savings. This will be funded by restructuring costs of approximately $15 million to be incurred and paid in 2022. We have a strong track record of simplifying the organization while lowering costs to serve. As a result, SG&A expenses are expected to decline meaningfully in the second half of the year. Second, turning to product mix, we're focusing on the parts of our product ranges with higher clinical value we can deliver more efficiently. This is expected to drive favorable sales mix, reduce complexity and lower costs, which is critical in this supply chain environment. Combined with pricing actions to offset higher costs, we expect significant uplift in gross profit for the remainder of the year. The expected benefit across Europe and North America is approximately $21 million in 2022. Even through COVID, we continued launching new products with compelling clinical value in all product categories. These products have been well-received by our customers and are expected to drive incremental sales growth. This will give us a strong foundation to narrow product lines this year and still achieve solid sales results. We anticipate a net benefit of approximately $3 million for the remainder of the year. In addition, further opportunities to simplify our organization are expected to reduce SG&A expense related to IT, administrative, and other spending. We expect these actions will drive sequentially improving financial results, enabling us to achieve full-year guidance of higher adjusted EBITDA and free cash flow the prior year. I'll now turn the call over to Kathy for a more detailed financial summary.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-